C₁₇₄H₂₈₃N₅₁O₅₅ · 3833.42 g/mol

Cagrilintide

Cagrilintide is a long-acting synthetic amylin analogue developed by Novo Nordisk. It acts on amylin and calcitonin receptors, slowing gastric emptying and inducing satiety signaling through pathways independent of the GLP-1 axis. The compound is the subject of significant Phase 3 clinical research as part of the CagriSema combination program (cagrilintide + semaglutide), where preliminary data suggests substantial additive effects on body weight and metabolic markers beyond what single-receptor agonists achieve. Cagrilintide is one of the most-watched next-generation incretin/amylin research compounds of 2026.